Federal Circuit Rules For Elan In Naproxen Patent Suit
The U.S. Court of Appeals for the Federal Circuit has reversed a lower court's decision to invalidate drug maker Elan's patent for controlled-release naproxen....To view the full article, register now.
Already a subscriber? Click here to view full article